Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of PCI
  • All clinical trials of systematic ballon angioplasty
    		•  

    TIMI 2 study, 1989

    Treatments

    Studied treatment CA 18 to 48 hrs
    Control treatment no CA unless spontaneous or exercise induced ischemia
    Concomittant treatment rt-PA

    Patients

    Patients patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) within four hours of the onset of chest pain thought to be caused by myocardial infarction
    Inclusion criteria delay from symptoms < 4 hrs, age<76
    Exclusion criteria contraindication to thrombolysis

    Method and design

    Randomized effectives 1636 / 1626 (studied vs. control)
    Design Factorial plan
    Blinding Open
    Follow-up duration 6 we
    Number of centre multicentre
    Geographic area United states
    Hypothesis Superiority
    Primary endpoint death + reinfarction at 42 days


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    In-hospital death

    85 / 1636
         76 / 1626
         1,11 [0,82;1,50]

    reinfarction

    105 / 1636
         94 / 1626
         1,11 [0,85;1,45]

    CABG

    195 / 1636
         170 / 1626
         1,14 [0,94;1,38]

    Major bleeding

    90 / 1636
         70 / 1626
         1,28 [0,94;1,73]

    Emergency CABG

    50 / 1636
         21 / 1626
         classic 2,37 [1,43;3,92]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    In-hospital death 85 / 1636 (5,2%) 76 / 1626 (4,7%) 1,11 [0,82;1,50]    
    reinfarction 105 / 1636 (6,4%) 94 / 1626 (5,8%) 1,11 [0,85;1,45]    
    CABG 195 / 1636 (11,9%) 170 / 1626 (10,5%) 1,14 [0,94;1,38]    
    Major bleeding 90 / 1636 (5,5%) 70 / 1626 (4,3%) 1,28 [0,94;1,73]    
    Emergency CABG 50 / 1636 (3,1%) 21 / 1626 (1,3%) 2,37 [1,43;3,92]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    In-hospital death 5,20% 4,67% 5,2‰
    reinfarction 6,42% 5,78% 6,4‰
    CABG 11,92% 10,46% 1,5%
    Major bleeding 5,50% 4,31% 1,2%
    Emergency CABG 3,06% 1,29% 1,8%


    Reference(s)

    Trials register # NA
    • ,. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group.. N Engl J Med 1989; 320:618-27
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend